Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 12-Month Low - Should You Sell?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) hit a new 52-week low during mid-day trading on Friday . The company traded as low as $16.98 and last traded at $17.26, with a volume of 127379 shares changing hands. The stock had previously closed at $17.54.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Scotiabank lifted their target price on Apellis Pharmaceuticals from $30.00 to $31.00 and gave the stock a "sector perform" rating in a report on Wednesday, April 2nd. The Goldman Sachs Group dropped their target price on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. Royal Bank of Canada decreased their price objective on Apellis Pharmaceuticals from $24.00 to $21.00 and set a "sector perform" rating for the company in a report on Monday, April 21st. JPMorgan Chase & Co. boosted their price target on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an "overweight" rating in a research report on Tuesday, March 4th. Finally, Wedbush reduced their target price on Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. Eight analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $45.28.

Apellis Pharmaceuticals Price Performance

The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The stock has a market cap of $2.34 billion, a PE ratio of -9.16 and a beta of 0.85. The business has a fifty day simple moving average of $22.49 and a two-hundred day simple moving average of $27.60.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its earnings results on Friday, February 28th. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm had revenue of $212.50 million for the quarter, compared to the consensus estimate of $197.92 million. During the same period in the prior year, the firm earned ($0.73) EPS. The company's revenue was up 45.2% compared to the same quarter last year. Research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,569 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total transaction of $139,781.90. Following the completion of the sale, the general counsel now owns 138,730 shares of the company's stock, valued at approximately $3,482,123. The trade was a 3.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last three months, insiders have sold 6,115 shares of company stock valued at $154,684. 6.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC lifted its holdings in shares of Apellis Pharmaceuticals by 2,707.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock worth $25,000 after acquiring an additional 758 shares during the last quarter. Signaturefd LLC grew its position in shares of Apellis Pharmaceuticals by 357.2% in the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company's stock worth $37,000 after buying an additional 918 shares during the last quarter. GF Fund Management CO. LTD. boosted its stake in Apellis Pharmaceuticals by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company's stock valued at $70,000 after acquiring an additional 573 shares in the last quarter. US Bancorp DE increased its position in shares of Apellis Pharmaceuticals by 70.0% during the fourth quarter. US Bancorp DE now owns 3,223 shares of the company's stock worth $103,000 after purchasing an additional 1,327 shares in the last quarter. Finally, Covestor Ltd boosted its position in shares of Apellis Pharmaceuticals by 1,819.2% in the 4th quarter. Covestor Ltd now owns 3,992 shares of the company's stock worth $127,000 after purchasing an additional 3,784 shares in the last quarter. 96.29% of the stock is owned by hedge funds and other institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).